T-CELL activation results in the release or shedding of a soluble form (45 kDa) of the cellular (55 kDa) low-affinity interleukin-2 receptor (z-chain) (slL-2R). The 
Introduction
The etiology of ulcerative colitis (UC) is unknown, but there is increasing evidence that immunological factors, including T-cell mediated immune functions, play a pathogenetic role in inflammatory bowel disease (IBD). 1'2 T-cell proliferation and differentiation depend primarily on the interplay between interleukin-2 (IL-2) and its specific receptor (IL-2R), which is expressed on activated, but not on resting T-cells. >s The biologically active, high-affinity IL-2R complex consists of a high-affinity 75 kDa /J-chain, and a low-affinity 55 kDa 0-chain. During activation, Tcells release a soluble (45 kDa) form of the low-affinity IL-2R z-chain (sIL-2R), which is detectable by enzyme-linked immunosorbent assay (ELISA) in serum and in inflamed gut tissue. [7] [8] [9] Circulating slL-2R levels may be of potential clinical value for the disease activity assessment in IBD, 1 and may also play a role in the regulation of T-cell activation, because it binds free IL-2. 
Results
The serum sIL-2R concentrations were significantly increased in UC patients (median 150 pg/ml, range 100-420) compared with controls (median 110 pg/ml, range 80-165) (p < 0.02).
As shown in Fig. 1 analysis.
There was no significant difference in slL-2R concentrations between patients with proctosigmoiditis (median 140pg/ml) and those with more extensive colitis (median 155 pg/ml) (p 0.19), (Fig. 2) .
Discussion
IL-2 is a T-cell-derived cytokine which plays a key role in the regulation of T-lymphocyte functions. Peripheral 31 In two previous studies on circulating slL-2R concentrations in patients with active UC, nearly all patients studied received either an oral glucocorticoid, azathioprine, sulphasalazine/5-aminosalicylic acid, or combinations thereof. 29'32 Although these drugs may interfere with different steps in the IL-2 dependent pathway of immune activation, 1'33 significantly higher serum levels of sIL-2R were found in patients with active UC, which is in accordance with the present findings, based on mainly untreated patients. Consequently, ongoing treatment with these drugs seems to have little influence on slL-2R levels, provided that these patients have active disease. Lamina propria lymphocytes from UC patients release significantly less amounts of sIL-2R in vitro as compared with controls. 32'34 This finding is somewhat difficult to reconcile with the repeated demonstration of increased sIL-2R levels in tissue homogenates from the same patient category, 19'29 but it illustrates that the precise cellular source of sIL-2R in UC is unknown. Apart from confirming elevated sIL-2R levels in patients with active and mainly untreated UC, the present study also shows that even UC patients in remission have significantly elevated serum sIL-2R levels.
There was no difference between circulating sIL-iR levels in patients with proctosigmoiditis and those with more extensive colitis, suggesting an equal degree of immune activation. This may be in accordance with the clinical experience that the intensity of immunosuppressive treatment should be chosen on the basis of the severity rather than the extent of the disease. 35 The biological role of raised sIL-iR levels is yet unknown, sIL-2R may have an immunoregulatory role by competing with the IL-iR complex on cell surfaces for free IL-2, thus facilitating a downregulation of the immune response.
11 Accordingly, when blood mononuclear cells from patients with active IBD are stimulated with IL-2 in vitro, the result is an increased cellular expression of low aflqnity IL-2R which, apart from binding free IL-2, also has been proposed to represent biologically active binding sites. 36 The release of sIL-2R is an IL-2 dependent phenomenon. 37 We conclude that the demonstration of increased serum slL-2R levels in patients with UC suggests an enhanced T-cell activation in this disorder. However, the overlaps between different disease stages, and between patients and controls, limit the general diagnostic value of this measure. Longitudinal studies are required to elucidate a possible role of serum sIL-2R as an additional marker of disease activity in individual patients who act as their own controls.
